FATE Fate Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FATE

Price (delayed)

$5.24

Market cap

$514.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.91

Enterprise value

$547.15M

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture ...

Highlights
FATE's revenue has surged by 72% year-on-year and by 40% since the previous quarter
The gross profit has surged by 72% year-on-year and by 40% since the previous quarter
The net income has contracted by 33% YoY but it has grown by 4.2% from the previous quarter
FATE's EPS is down by 30% year-on-year but it is up by 4.6% since the previous quarter
The company's quick ratio fell by 45% YoY and by 16% QoQ
The company's equity fell by 29% YoY and by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.fatetherapeutics.com
Peers: SRPT BDX PTCT RNA

Key stats

What are the main financial stats of FATE
Market
Shares outstanding
98.16M
Market cap
$514.37M
Enterprise value
$547.15M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.05
Price to sales (P/S)
5.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.68
Earnings
Revenue
$96.3M
EBIT
-$281.72M
EBITDA
-$267.96M
Free cash flow
-$283.77M
Per share
EPS
-$2.91
Free cash flow per share
-$2.93
Book value per share
$4.98
Revenue per share
$0.99
TBVPS
$7.29
Balance sheet
Total assets
$705.56M
Total liabilities
$221.62M
Debt
$109.34M
Equity
$483.94M
Working capital
$388.02M
Liquidity
Debt to equity
0.23
Current ratio
4.4
Quick ratio
4.3
Net debt/EBITDA
-0.12
Margins
EBITDA margin
-278.3%
Gross margin
100%
Net margin
-292.5%
Operating margin
-320.2%
Efficiency
Return on assets
-36.1%
Return on equity
-50.9%
Return on invested capital
-39.5%
Return on capital employed
-47.6%
Return on sales
-292.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FATE stock price

How has the Fate Therapeutics stock price performed over time
Intraday
1.75%
1 week
-5.92%
1 month
-14.1%
1 year
-85.82%
YTD
-48.07%
QTD
-48.07%

Financial performance

How have Fate Therapeutics's revenue and profit performed over time
Revenue
$96.3M
Gross profit
$96.3M
Operating income
-$308.39M
Net income
-$281.72M
Gross margin
100%
Net margin
-292.5%
FATE's revenue has surged by 72% year-on-year and by 40% since the previous quarter
The gross profit has surged by 72% year-on-year and by 40% since the previous quarter
FATE's operating income is down by 42% year-on-year
The net income has contracted by 33% YoY but it has grown by 4.2% from the previous quarter

Growth

What is Fate Therapeutics's growth rate over time

Valuation

What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
1.05
P/S
5.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.68
FATE's EPS is down by 30% year-on-year but it is up by 4.6% since the previous quarter
FATE's price to book (P/B) is 86% lower than its 5-year quarterly average of 7.6 and 75% lower than its last 4 quarters average of 4.1
The company's equity fell by 29% YoY and by 7% QoQ
The stock's price to sales (P/S) is 96% less than its 5-year quarterly average of 135.5 and 85% less than its last 4 quarters average of 34.0
FATE's revenue has surged by 72% year-on-year and by 40% since the previous quarter

Efficiency

How efficient is Fate Therapeutics business performance
The ROE has plunged by 77% YoY and by 4.3% from the previous quarter
Fate Therapeutics's return on assets has shrunk by 69% YoY and by 2.6% QoQ
The ROIC has plunged by 65% YoY and by 2.1% from the previous quarter
FATE's return on sales is up by 31% since the previous quarter and by 23% year-on-year

Dividends

What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FATE.

Financial health

How did Fate Therapeutics financials performed over time
The company's quick ratio fell by 45% YoY and by 16% QoQ
FATE's current ratio is down by 44% YoY and by 15% from the previous quarter
The debt is 77% smaller than the equity
The company's debt to equity rose by 35% YoY and by 10% QoQ
The company's equity fell by 29% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.